Landscapes / Companies
Cogent Biosciences, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
4
in active trials · 5 in all
Trials
6 active
8 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
Phase 3 | — | |||
| How it works | Blocks a kinase | ||||
| Also tested for | Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN) and 12 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma and 10 more | ||||
| Open drug page | |||||
— |
Phase 1 | May 2028Phase 1 trial completes | |||
| Next date | May 2028 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer and 4 more | ||||
| Open drug page | |||||
— |
Phase 1 | Jul 2029Phase 1 trial completes | |||
| Next date | Jul 2029 · Phase 1 trial completes | ||||
| Also tested for | PIK3CA Mutations, Advanced Solid Tumors, Adult and 3 more | ||||
| Open drug page | |||||
About
- No active trial
- ACTR707
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021